Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis
Idraparinux showed no clear difference in recurrent venous thromboembolism compared with standard therapy (low certainty).
1 finding from 1 review
Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
2 findings from 1 review
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
Idraparinux showed no clear difference in all‐cause mortality compared with standard therapy (low certainty).
1 finding from 1 review
Heparin‐induced thrombocytopaenia · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis
It is very uncertain whether idraparinux changes all harmful effects compared with standard therapy (very low certainty).
1 finding from 1 review
Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis
It is very uncertain whether low molecular weight heparin and idraparinux changes recurrent venous thromboembolism compared with standard therapy (very low certainty).
1 finding from 1 review
Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
2 findings from 1 review
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Heparin‐induced thrombocytopaenia · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
Idrabiotaparinux showed no clear difference in all‐cause mortality compared with idraparinux (low certainty).
1 finding from 1 review
Heparin‐induced thrombocytopenia ‐ not reported · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis
It is very uncertain whether idrabiotaparinux changes all harmful effects compared with idraparinux (very low certainty).
1 finding from 1 review
Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis
Idrabiotaparinux showed no clear difference in recurrent venous thromboembolism compared with idraparinux (low certainty).
1 finding from 1 review
Major bleeding during the initial treatment ‐ not reported · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis
Idrabiotaparinux may leads to lower major bleeding compared with idraparinux (low certainty).
1 finding from 1 review